Edition:
United Kingdom

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

4.65USD
19 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.65
Open
$4.60
Day's High
$4.75
Day's Low
$4.55
Volume
8,062
Avg. Vol
19,888
52-wk High
$8.35
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Kempharm Initiates Pivotal Efficacy Trial Of KP415
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Kempharm Inc ::KEMPHARM INITIATES PIVOTAL EFFICACY TRIAL OF KP415.KEMPHARM INC - ENROLLMENT IN TRIAL IS EXPECTED TO TOTAL APPROXIMATELY 140 PATIENTS ACROSS FIVE CLINICAL SITES IN UNITED STATES.  Full Article

KemPharm says completed meeting with FDA on KP415
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - KemPharm Inc -:KemPharm completes successful end-of-Phase 2 meeting on KP415 with FDA.KemPharm - held meeting to discuss status of proposed clinical, non-clinical,abuse liability studies, among others for submission of NDA for KP415​.KemPharm - ‍meeting with FDA helped confirm remain on schedule in KP415 development program, including work required to complete other standard protocols​.  Full Article

KemPharm posts Q3 loss per share $0.68
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - KemPharm Inc :KemPharm reports third quarter 2017 results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.  Full Article

KemPharm says KP484 allowed to proceed to clinical studies​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Kempharm Inc :kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies.Kempharm inc - ‍u.s. Food and drug administration has completed its safety review of investigational new drug application for kp484​.  Full Article

Kempharm files IND application to begin human clinical trials for KP201/IR
Tuesday, 25 Oct 2016 

Kempharm Inc : Kempharm files IND for KP201/IR, a single-entity benzhydrocodone HCL immediate release abuse-deterrent prodrug for the treatment of acute pain . We intend to initiate human clinical trials of KP201/IR in first half of 2017 .Remain on target for a potential submission in 2018 of KP201/IR new drug application.  Full Article

Kempharm files for potential mixed shelf of upto $150 mln
Monday, 3 Oct 2016 

Kempharm Inc :Kempharm Inc files for potential mixed shelf of upto $150 million - SEC filing.  Full Article

KemPharm Q2 loss per share $0.58
Wednesday, 10 Aug 2016 

KemPharm Inc : Kempharm Inc reports second quarter 2016 results .Q2 loss per share $0.58.  Full Article

BRIEF-Kempharm Announces Positive Topline Results From KP415 Pharmacokinetic Study In Children And Adolescents With ADHD

* KEMPHARM ANNOUNCES POSITIVE TOPLINE RESULTS FROM KP415 PHARMACOKINETIC STUDY IN CHILDREN AND ADOLESCENTS WITH ADHD